Merrem is an intravenous antibiotic used to treat serious infections [1]. It is a carbapenem antibiotic, a class of drugs known for their broad-spectrum activity against a wide range of bacteria, including many that are resistant to other antibiotics [2][3]. Merrem is effective against susceptible gram-positive and gram-negative bacteria, as well as anaerobic organisms [1].
What specific infections can Merrem treat?
Merrem is indicated for the treatment of complicated intra-abdominal infections, complicated skin and skin-structure infections, and bacterial meningitis [1]. For intra-abdominal infections, it is typically used in combination with another antibiotic, such as metronidazole [1]. Its use in bacterial meningitis is generally reserved for cases where other treatments have failed or are not suitable [1].
How does Merrem work to kill bacteria?
Merrem functions by inhibiting the synthesis of bacterial cell walls [2]. It binds to penicillin-binding proteins (PBPs), which are essential enzymes involved in the final stages of cell wall formation. By blocking these PBPs, meropenem disrupts the structural integrity of the bacterial cell wall, leading to cell death [2][3].
When does the patent for Merrem expire?
The patent protection for meropenem has largely expired, allowing for the development and marketing of generic versions [4]. For instance, the primary patents for meropenem expired around 2011-2013, opening the door for generic competition [4]. DrugPatentWatch.com tracks patent expiry dates and exclusivity periods for pharmaceuticals [5].
Who makes generic versions of Merrem?
Multiple pharmaceutical companies manufacture generic versions of meropenem. These include companies such as Fresenius Kabi, Mylan (now Viatris), Teva Pharmaceuticals, and others [6][7]. The availability of generics has typically led to a decrease in the cost of the medication [8].
How does Merrem compare to other carbapenem antibiotics?
Merrem (meropenem) shares similarities with other carbapenems like imipenem/cilastatin and ertapenem. However, there are differences in their spectrum of activity, routes of administration, and approved indications. Meropenem generally has a broader spectrum than ertapenem and is active against Pseudomonas aeruginosa, whereas ertapenem is not [3]. Compared to imipenem, meropenem is less susceptible to degradation by renal dehydropeptidase-I, potentially leading to higher and more predictable drug concentrations in the body [3].
What are the potential side effects of Merrem?
Common side effects associated with meropenem include nausea, vomiting, diarrhea, headache, and rash [1]. More serious, though less frequent, side effects can involve severe allergic reactions, Clostridioides difficile-associated diarrhea, and neurological effects such as seizures [1]. Patients with a history of hypersensitivity to other beta-lactam antibiotics may also be at risk for allergic reactions to meropenem [1].